Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma

Gregory A. Wiseman*, Christine A. White, Richard B. Sparks, William D. Erwin, Donald A. Podoloff, Dominick Lamonica, Nancy L. Bartlett, J. Anthony Parker, William L. Dunn, Stewart M. Spies, Richard Belanger, Thomas E. Witzig, Bryan R. Leigh

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

163 Scopus citations

Fingerprint Dive into the research topics of 'Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences